July 1, 2022

HMS & NQF Update

The HMS Coordinating Center received additional funding through the Gordon and Betty Moore Foundation to further analyze opportunities of misdiagnosis within our antimicrobial registry. Over the last 1-2 years, we have conducted in-depth case reviews with physician members from across the Collaborative to confirm our measures for assessing the diagnosis of pneumonia and asymptomatic bacteriuria/urinary tract infection. As a result of these case reviews, we have identified our method of assessing is largely accurate. In October 2021, a technical expert panel was conducted and consisted of representatives from the following societies:  American College of Emergency Medicine, Centers for Disease Control and Prevention, Infectious Disease Society of America, Pew Research Center, Society for Healthcare Epidemiology of America, Society to Improve Diagnosis in Medicine, Association for Professionals in Infection Control and Epidemiology, Society of Infectious Diseases Pharmacists, The Joint Commission, American Academy of Emergency Medicine, Society of Hospital Medicine, American College of Radiology, American College of Chest Physicians, American Thoracic Society, American Urological Association. A patient panel was conducted in December. The HMS leadership team submitted the antimicrobial measures of assessing the diagnosis of pneumonia and asymptomatic bacteriuria/urinary tract infection to the National Quality Forum (NQF) in April 2022.